Back to Awarded Treatment Trials
Awarded Trial: 06TGF-911
Grant ID
06TGF-911
Illness
Schizophrenia
Primary Drug/Intervention
L-Theanine
Primary Dosage
400 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Ritsner
Sample Size
60
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
PANNS, CGI, ANS, CDSS, HAM-A, SUMD, GAF, the Talbieh Brief Distress Inventory, the State/Trait Anxiety Inventory, QLS, Q-LES-Q, ESRS, BARS, CANTAB
Results
Sixty (60) patients with schizophrenia or schizoaffective disorder were randomized to L-theanine 400 mg/day for 8 weeks as an adjunct medication. Those on L-theanine had a significant improvement in anxiety, PANSS-positive, and general psychopathology symptoms.
Publication
Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V. L-Theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011 Jan;72(1):34-42.
Link
http://www.ncbi.nlm.nih.gov/pubmed/21208586
PI Name
Michael Ritsner
Degree
MD
Center
N/A
Institution
Sha'ar Menashe Mental Health Center
Address
Mobile Post Hefer 38814
City or Town
Hadera
State or Province
N/A
Zip or Postal Code
38814
Country
Israel
Email Address
ritsner@shaar-menashe.org.il